methamphetamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1732 537-46-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methamphetamine
  • (S)-Methamphetamine
  • methylamphetamine
  • D-Methylamphetamine
  • methamphetamine hydrochloride
  • metamfetamine
  • methamphetamine HCl
A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.
  • Molecular weight: 149.24
  • Formula: C10H15N
  • CLOGP: 1.89
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -2.21
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1000 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.92 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 67 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1943 FDA RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 3967.93 49.81 895 2998 71623 63413506
Toxicity to various agents 1298.40 49.81 501 3392 246749 63238380
Completed suicide 565.78 49.81 240 3653 145433 63339696
Cardio-respiratory arrest 255.35 49.81 106 3787 59853 63425276
Respiratory arrest 232.76 49.81 84 3809 32561 63452568
Death 231.72 49.81 187 3706 374194 63110935
Cardiac arrest 223.18 49.81 110 3783 92435 63392694
Amphetamines positive 91.53 49.81 15 3878 187 63484942
Overdose 91.32 49.81 67 3826 115011 63370118
Substance abuse 77.58 49.81 23 3870 4784 63480345
Opiates positive 75.41 49.81 14 3879 372 63484757
Prescription drug used without a prescription 54.63 49.81 15 3878 2371 63482758
Exposure to toxic agent 53.69 49.81 18 3875 5569 63479560
Drug screen positive 52.66 49.81 16 3877 3613 63481516
Renal infarct 51.94 49.81 13 3880 1434 63483695

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 6281.08 59.20 1722 5031 97374 34852804
Toxicity to various agents 1995.46 59.20 890 5863 199472 34750706
Completed suicide 336.28 59.20 218 6535 97950 34852228
Respiratory arrest 315.52 59.20 138 6615 27905 34922273
Cardio-respiratory arrest 266.52 59.20 153 6600 55120 34895058
Cardiac arrest 202.43 59.20 159 6594 96000 34854178
Death 190.46 59.20 301 6452 397748 34552430
Exposure to toxic agent 159.37 59.20 49 6704 3626 34946552
Overdose 138.57 59.20 125 6628 90934 34859244
Prescription drug used without a prescription 134.07 59.20 38 6715 2116 34948062
Incorrect route of product administration 116.49 59.20 57 6696 14788 34935390
Intentional product misuse 103.46 59.20 79 6674 45532 34904646
Amphetamines positive 90.86 59.20 18 6735 203 34949975
Drug abuser 88.36 59.20 32 6721 3922 34946256
Pulmonary oedema 87.83 59.20 73 6680 47456 34902722
Respiratory depression 86.21 59.20 48 6705 16197 34933981
Serotonin syndrome 84.78 59.20 51 6702 19882 34930296
Substance abuse 83.77 59.20 37 6716 7604 34942574
Brain oedema 79.29 59.20 43 6710 13778 34936400
Accidental overdose 66.74 59.20 44 6709 20096 34930082
Opiates positive 63.49 59.20 16 6737 565 34949613

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug abuse 9985.09 52.25 2539 7786 160152 79573911
Toxicity to various agents 3279.07 52.25 1397 8928 420143 79313920
Completed suicide 814.99 52.25 462 9863 245305 79488758
Respiratory arrest 537.82 52.25 221 10104 57329 79676734
Cardio-respiratory arrest 536.40 52.25 267 10058 108243 79625820
Death 465.29 52.25 460 9865 566054 79168009
Cardiac arrest 408.81 52.25 262 10063 171834 79562229
Overdose 233.68 52.25 192 10133 184014 79550049
Exposure to toxic agent 204.70 52.25 67 10258 9091 79724972
Prescription drug used without a prescription 187.24 52.25 52 10273 4033 79730030
Intentional product misuse 179.89 52.25 126 10199 95039 79639024
Amphetamines positive 159.14 52.25 29 10296 313 79733750
Respiratory depression 150.97 52.25 73 10252 27557 79706506
Accidental overdose 134.31 52.25 76 10249 39505 79694558
Opiates positive 133.42 52.25 30 10295 974 79733089
Incorrect route of product administration 132.01 52.25 72 10253 34857 79699206
Pulmonary oedema 117.97 52.25 95 10230 88159 79645904
Substance abuse 106.87 52.25 43 10282 10483 79723580
Drug abuser 106.71 52.25 37 10288 5976 79728087
Drug screen positive 91.21 52.25 33 10292 6030 79728033
Serotonin syndrome 90.56 52.25 62 10263 44965 79689098
Fatigue 83.64 52.25 11 10314 929716 78804347
Diarrhoea 80.19 52.25 10 10315 880479 78853584
Pulmonary congestion 75.97 52.25 46 10279 27054 79707009
Brain oedema 71.12 52.25 43 10282 25220 79708843
Postmortem blood drug level 66.40 52.25 14 10311 334 79733729
Drug ineffective 65.91 52.25 29 10296 1080884 78653179
Poisoning 60.98 52.25 39 10286 25233 79708830
Nausea 59.39 52.25 25 10300 957171 78776892
Intentional overdose 56.32 52.25 69 10256 105891 79628172
Dyspnoea 55.40 52.25 21 10304 857004 78877059
Rash 53.97 52.25 6 10319 578352 79155711
Accidental poisoning 53.22 52.25 16 10309 1641 79732422
Arthralgia 53.18 52.25 6 10319 571797 79162266

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06BA03 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
FDA CS M0001015 Amphetamines
FDA PE N0000175372 Appetite Suppression
FDA EPC N0000175425 Amphetamine Anorectic
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics
CHEBI has role CHEBI:35337 analeptic
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:78298 environmental contaminants
FDA PE N0000175651 Increased Sympathetic Activity
FDA PE N0000175729 Central Nervous System Stimulation
FDA EPC N0000175739 Central Nervous System Stimulant

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Attention deficit hyperactivity disorder indication 406506008
Obesity indication 414916001 DOID:9970
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Bipolar disorder contraindication 13746004 DOID:3312
Hepatic encephalopathy contraindication 13920009 DOID:13413
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:557
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Acute exacerbation of asthma contraindication 708038006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.73 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter INHIBITOR Ki 7.61 PDSP CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.08 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 6.13 PDSP
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 7.91 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 5 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.13 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.09 PDSP
Trace amine-associated receptor 1 GPCR AGONIST EC50 5.89 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 5.38 PDSP
Synaptic vesicular amine transporter Transporter Ki 5.61 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 5.28 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 6.88 CHEMBL
Trace amine-associated receptor 1 GPCR EC50 7.15 CHEMBL

External reference:

IDSource
4019821 VUID
N0000147910 NUI
D02242 KEGG_DRUG
51-57-0 SECONDARY_CAS_RN
4018483 VANDF
4019821 VANDF
C0025611 UMLSCUI
CHEBI:6809 CHEBI
B40 PDB_CHEM_ID
CHEMBL1201201 ChEMBL_ID
DB01577 DRUGBANK_ID
CHEMBL1200952 ChEMBL_ID
D008694 MESH_DESCRIPTOR_UI
10836 PUBCHEM_CID
1879 INN_ID
4803 IUPHAR_LIGAND_ID
44RAL3456C UNII
6816 RXNORM
1988 MMSL
5066 MMSL
d00805 MMSL
001797 NDDF
004722 NDDF
387329009 SNOMEDCT_US
387499002 SNOMEDCT_US
8692006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0389 TABLET 5 mg ORAL ANDA 25 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0389 TABLET 5 mg ORAL ANDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-102 TABLET 5 mg ORAL NDA 25 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 55292-104 TABLET 5 mg ORAL NDA 25 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections
Methamphetamine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 68308-115 TABLET 5 mg ORAL ANDA 29 sections
Desoxyn HUMAN PRESCRIPTION DRUG LABEL 1 70868-820 TABLET 5 mg ORAL NDA 21 sections